Prophylactic Penehyclidine Hydrochloride Inhalation and 3-year Outcome After Surgery

PHASE4CompletedINTERVENTIONAL
Enrollment

864

Participants

Timeline

Start Date

March 12, 2019

Primary Completion Date

December 1, 2021

Study Completion Date

December 1, 2021

Conditions
Postoperative ComplicationsLong-term Outcome
Interventions
DRUG

Penehyclidine inhalation

Penehyclidine inhalation is administered by inhalation (penehyclidine hydrochloride 0.5 mg/0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients

DRUG

Placebo inhalation

Placebo inhalation is administered by inhalation (water for injection 0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygendriven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.

Trial Locations (1)

100034

Peking University First Hospital, Beijing

All Listed Sponsors
lead

Peking University First Hospital

OTHER

NCT03868709 - Prophylactic Penehyclidine Hydrochloride Inhalation and 3-year Outcome After Surgery | Biotech Hunter | Biotech Hunter